Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Characteristics of the cohort (n=170). Characteristics | All | Queen Mary Hospital(n=109) | Tung Wah Hospital(n=61) | P-value: 25-hydroxyvitamin D (nmol/L) | 85.5 ± 26.5 | 87.5 ± 27.4 | 81.8 ± 24.3 | 0.200

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Association of baseline glycaemic status with BMD change after 12 doses of romosozumab: a retrospective cohort study of 170 patients

Source: Article title.

Sample size was not calculated a priori, and all consecutive patients were included.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Association of baseline glycaemic status with BMD change after 12 doses of romosozumab: a retrospective cohort study of 170 patients

Cohort study · Frontiers in Endocrinology · 2026

Original publication title

Association of baseline glycaemic status with BMD change after 12 doses of romosozumab: a retrospective cohort study of 170 patients

Kimberly H. Tsoi; Xi Xiong; Xiaodong Liu; Chun-Ho Wong; Carol H. Y. Fong; Matrix M. H. Fung; Eunice K. H. Leung; Alan C. H. Lee; Tai-Pang Ip; Kathryn C. B. Tan; Chi-Ho Lee; Yu-Cho Woo; Manju Chandran; Elena Tsourdi; David T. W. Lui

Copyright © 2026 Tsoi, Xiong, Liu, Wong, Fong, Fung, Leung, Lee, Ip, Tan, Lee, Woo, Chandran, Tsourdi and Lui.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This real-world study showed BMD gains of 12% at the LS and 3.5% at the hip with 12 doses of romosozumab. No statistically significant association was identified between baseline glycaemic category and one-year BMD change during romosozumab treatment. However, the relatively small diabetes subgroup limits the precision of this estimate.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

We evaluated whether dysglycaemia is an independent factor associated with bone mineral density (BMD) gain during romosozumab treatment.

Source: Objective

Abstract: What methods does the paper describe?

We included all patients who initiated and received 12 doses of romosozumab in two Osteoporosis Centres from January 2019 to March 2025 and had dual-energy X-ray absorptiometry performed at baseline and upon completion of romosozumab. The cohort was divided into three groups. Diabetes was defined by physician diagnosis, glycated haemoglobin (HbA1c) ≥ 6.5%, or anti-diabetic medication use. Among those without known diabetes, HbA1c 5.7%: 6.4% defined prediabetes and HbA1c ≤ 5.6% defined normoglycaemia. Percentage of BMD (%BMD) gain while on romosozumab was calculated.

Multivariable linear regression analysis was used to identify independent factors associated with %BMD gain.

Source: Methods

Abstract: Results

A total of 170 patients were included (age 71.6 ± 9.6 years; 167 women, 3 men; body mass index (BMI) 21.0 ± 3.6 kg/m2): 59.4% had normoglycaemia, 25.9% prediabetes, and 14.7% diabetes (all type 2). Of these, 64.1% had prior antiresorptive exposure. Baseline mean BMD T-scores (95% CI) were −3.0 (−3.2, −2.9) (lumbar spine, LS), −2.9 (−3.1, −2.8) (femoral neck, FN), and −2.6 (−2.7, −2.4) (total hip, TH). In total, 69.4% had prior fractures. Overall %BMD gain was 12.1% (95% CI 10.5%: 13.7%) (LS), 3.6% (95% CI 2.4%: 4.7%) (FN), and 3.4% (95% CI 2.5%: 4.3%) (TH).

Across the three glycaemic categories, %BMD gain did not differ (LS: p = 0.821; FN: p = 0.776; TH: p = 0.985). HbA1c did not correlate with %BMD gain. Baseline BMD T-score and prior antiresorptive treatment were the independent factors inversely associated with %BMD gain.

Source: Results

Abstract: Conclusion

This real-world study showed BMD gains of 12% at the LS and 3.5% at the hip with 12 doses of romosozumab. No statistically significant association was identified between baseline glycaemic category and one-year BMD change during romosozumab treatment. However, the relatively small diabetes subgroup limits the precision of this estimate.

Source: Conclusion
Authors’ abstract

Objective

We evaluated whether dysglycaemia is an independent factor associated with bone mineral density (BMD) gain during romosozumab treatment.

Methods

We included all patients who initiated and received 12 doses of romosozumab in two Osteoporosis Centres from January 2019 to March 2025 and had dual-energy X-ray absorptiometry performed at baseline and upon completion of romosozumab. The cohort was divided into three groups. Diabetes was defined by physician diagnosis, glycated haemoglobin (HbA1c) ≥ 6.5%, or anti-diabetic medication use. Among those without known diabetes, HbA1c 5.7%: 6.4% defined prediabetes and HbA1c ≤ 5.6% defined normoglycaemia. Percentage of BMD (%BMD) gain while on romosozumab was calculated.

Multivariable linear regression analysis was used to identify independent factors associated with %BMD gain.

Results

A total of 170 patients were included (age 71.6 ± 9.6 years; 167 women, 3 men; body mass index (BMI) 21.0 ± 3.6 kg/m2): 59.4% had normoglycaemia, 25.9% prediabetes, and 14.7% diabetes (all type 2). Of these, 64.1% had prior antiresorptive exposure. Baseline mean BMD T-scores (95% CI) were −3.0 (−3.2, −2.9) (lumbar spine, LS), −2.9 (−3.1, −2.8) (femoral neck, FN), and −2.6 (−2.7, −2.4) (total hip, TH). In total, 69.4% had prior fractures. Overall %BMD gain was 12.1% (95% CI 10.5%: 13.7%) (LS), 3.6% (95% CI 2.4%: 4.7%) (FN), and 3.4% (95% CI 2.5%: 4.3%) (TH).

Across the three glycaemic categories, %BMD gain did not differ (LS: p = 0.821; FN: p = 0.776; TH: p = 0.985). HbA1c did not correlate with %BMD gain. Baseline BMD T-score and prior antiresorptive treatment were the independent factors inversely associated with %BMD gain.

Conclusion

This real-world study showed BMD gains of 12% at the LS and 3.5% at the hip with 12 doses of romosozumab. No statistically significant association was identified between baseline glycaemic category and one-year BMD change during romosozumab treatment. However, the relatively small diabetes subgroup limits the precision of this estimate.

Publication and source details

Original title: Association of baseline glycaemic status with BMD change after 12 doses of romosozumab: a retrospective cohort study of 170 patients

Kimberly H. Tsoi; Xi Xiong; Xiaodong Liu; Chun-Ho Wong; Carol H. Y. Fong; Matrix M. H. Fung; Eunice K. H. Leung; Alan C. H. Lee; Tai-Pang Ip; Kathryn C. B. Tan; Chi-Ho Lee; Yu-Cho Woo; Manju Chandran; Elena Tsourdi; David T. W. Lui

Frontiers in Endocrinology · 2026

* Correspondence: David T. W. Lui, dtwlui@hku.hkCopyright © 2026 Tsoi, Xiong, Liu, Wong, Fong, Fung, Leung, Lee, Ip, Tan, Lee, Woo, Chandran, Tsourdi and Lui.2026Tsoi, Xiong, Liu, Wong, Fong, Fung, Leung, Lee, Ip, Tan, Lee, Woo, Chandran, Tsourdi and Luihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:27:06.413532+00:00

DOI: 10.3389/fendo.2026.1941784 · PMC13713262